## NATURE REVIEWS DRUG DISCOVERY

### **EDITORIAL OFFICES**

DON NatureReviews@nature.com The Macmillan Building, 4 Crinan Street, London N1 oXW

Tel: +44 (0)20 7843 3601; Fax: +44 (0)20 7843 3629

**EDITOR:** Adam Smith

SENIOR EDITORS: Melanie Brazil, Peter Kirkpatrick ASSOCIATE EDITORS (NEWS): Simon Frantz, Clare Ellis

ASSISTANT EDITOR: Suzanne Farley **COPY EDITOR:** Daniel Jones **ART EDITOR:** Susanne Harris

ART CONTROLLER: Nicola Barker SENIOR ART EDITORS: Radha Clelland **DEPUTY PRODUCTION EDITOR:** Simon Fenwick

MANAGING PRODUCTION EDITOR: Judith Shadwell OFFICE MANAGER: Luisa Estanislao

EDITORIAL ASSISTANTS: Shay Hussey, Simone Zaremba WORLD WIDE WEB: http://www.nature.com/reviews DIRECTOR OF ELECTRONIC PUBLISHING SERVICES: Don Fick

GLOBAL ELECTRONIC PRODUCTION MANAGER: Jeremy Macdonald **ELECTRONIC PRODUCTION MANAGER, UK:** Amanda Ward **ELECTRONIC PRODUCTION COORDINATORS:** Nick Allin,

Kate Lewandowska, Stephen Shields

PRODUCTION CONTROLLER: Kelly Farrel

### MANAGEMENT OFFICES

MANAGEMENT OFFICES
LONDON nature@nature.com The Macmillan Building,
4 Crinan Street, London N1 9XW
Tel: +44 (0)20 7833 4000; Fax: +44 (0)20 7843 4596/7
MANAGING DIRECTOR: Annette Thomas
PUBLISHING DIRECTOR: Jayne Marks
PUBLISHER: Peter Collins
EXECUTIVE EDITOR: Alison Mitchell
ASSOCIATE DIRECTORS: Jenny Henderson, Tony Rudland
EDITOR: AILSON MITCHER PUBLICATIONS: Philip Campbell
GLOBAL HEAD OF ADVERTISING SALES: Fabien Savenay
SENIOR MARKETING MANAGER: Philippa Rego
MARKETING MANAGER: Anna Duguid
PRODUCTION MANAGER: Young Strong
PRODUCTION CONTROLLER: Kelly Farrell

NEW YORK nature@natureny.com 345 Park Avenue South, 10th Floor, New York, NY 10010-1707 Tel: +1 212 726 9200; Fax: +1 212 696 9006 CHIEF TECHNOLOGY OFFICER: Howard Ratner GROUP DISPLAY ADVERTISING DIRECTOR: Andrea Pellegrino NATUREJOBS PUBLISHER: Ben Crowe HEAD OF NATURE RESEARCH & REVIEWS MARKETING: Sara Girard

TOKYO nature@naturejpn.com MG Ichigaya Building (5F), 19-1 Haraikatamachi, Shinjuku-ku, Tokyo 162-0841 Tel: +81 3 3267 8751; Fax: +81 3 3267 8746 **ASIA-PACIFIC PUBLISHER:** Antoine E Bocquet MANAGER: Koichi Nakamura
ASIA-PACIFIC SALES DIRECTOR: Hideki Watanabe SENIOR MARKETING MANAGER: Martin Paine Tel: +81 3 3267 8751; Fax: +81 3 3267 8746 MARKETING EXECUTIVE: Takesh Murakami

INDIA 5A/12 Ansari Road, Daryganj, New Delhi 110 002, India Tel/Fax: +01 SALES AND MARKETING MANAGER: Harpal Singh Gill

# DISPLAY ADVERTISING

US SALES DIRECTOR: Andrea Pellegrino Tel: +1 212 726 9243; Fax: +1 212 696 9481 GLOBAL HEAD OF DISPLAY ADVERTISING SALES: John Michael Tel: +44 (o) 20 7843 4960; Fax: +44 (o) 20 7843 4996 INTERNET SALES MANAGERS: EUROPE: Gerard Preston Tel: +44 (o) 20 7843 4898; **US:** Lynne Stickrod Tel: +1 415 781 6422 **EUROPEAN SALES MANAGER:** Gerard Preston EUKUPEAN 3ALS 4960 Tel: +44 (0) 20 7843 4960 UK SALES MANAGER: Roger Goncalves Tel: +444 (0) 20 7843 4960 US EAST; Jim Breault Tel: +1 212 726 9334; Fax: +1 212 726 9481 MIDWEST: Mike Stack Tel: +1 847 498 4520; Fax: +1 847 498 5911 WEST: Lynne Stickrod/George Lui Tel:+1 415 781 3804; Fax: +1 415 781 3805

SALES EXECUTIVES

UK: Lisa Lloyd, James Buckley
Tel: +44 (o) 20 7843 4960; Fax: +44 (o) 20 7843 4996

NETHERLANDS AND SCANDINAVIA: Claire Hines Tel: +44 (o) 20 7843 4960; Fax: +44 (o) 20 7843 4996

SOUTHERN GERMANY, SWITZERLAND AND AUSTRIA:

SOUTHERN GERMANY, SWITZERLAND AND AUSTRIA: Sabine Hugi-Fürst
Tel: +4152761 3386; Fax: +4152761 3419
CENTRAL GERMANY, FRANCE, BENELUX: Sophie Niklas Tel: +44 207 843 4966 Fax: +44 207 843 4966
NORTHERN GERMANY AND ITALY: Kate Woods Tel: +49 89 54 9057 126; Fax: +49 89 54 9057-26; Fax: +49 89 54 9057-26; JAPAN: nature@naturejpn.com Hideki Watanabe, Nature Japan KK Tel: +81 3 3267 8751; Fax: +81 3 3267 8746

Original design by Jane Walker

Copyright © 2003 Nature Publishing Group Printed in Wales by Cambrian Printers on acid-free paper

orldwide, the size of ageing populations is increasing, adding greater urgency to the need for new therapies for age-related diseases. Clark and Yorio review new approaches to the treatment of impaired vision caused by glaucoma and macular degeneration, and the market for ophthalmic drugs is analysed by Renaud and Xuereb. Rheumatoid arthritis also predominantly affects the elderly, and Smolen and Steiner describe advances in our understanding of the pathogenesis of this debilitating condition that have led to novel drugs and also pointed to future approaches for drug development. The prospects for the effective treatment of chronic pain caused by nerve damage have improved with the discovery that neurotrophic factors are key to neuropathic pain pathways. As Porreca and colleagues highlight, therapeutically targeting neurotrophins might have the potential to reverse this persistent pain state. Another neurological disorder, schizophrenia, is the focus of this month's 'Fresh from the Pipeline' on aripiprazole, a recently approved atypical antipsychotic with a novel therapeutic profile. Getting a new drug to market is not, however, always the end of the story. Fermini and Fossa consider the impact of the problem of QT interval prolongation — which has led to the withdrawal of several drugs — on drug development. The need for more critical scrutiny of screening assays used in early drug development is highlighted by Kenakin in this month's 'Guide to Drug Discovery' article, showing that the various natural and recombinant cellular assay systems used in lead optimization for compounds targeted against G-protein-coupled receptors can yield significantly different results. Finally, Merril and colleagues show that looking back can be another way of moving forward in their Perspective on the potential for bacteriophage — first used clinically in 1915 — to combat pathogenic bacteria.









Adam Smith

Melanie Brazil

Peter Kirkpatrick

Simon Frantz